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Purpose: A preoperative risk score (PRS) to predict outcome of patients with intrahepatic chol-
angiocarcinoma treated by liver surgery could be clinically relevant.To assess accuracy for broadly
adoption, external validation of predictive models on independent datasets is crucial.
The objective of this study was to externally validate the score for prediction of long-term outcomes after
liver surgery for intrahepatic cholangiocarcinoma proposed by Sasaki et al. and based on preoperative
albumin, neutrophil-to-lymphocytes-ratio, CA19-9 and tumor size.
Methods: Patients treated by liver surgery for intrahepatic cholangiocarcinoma at 11 international HPB
centers from 2001 to 2018 were included in the external validation cohort. Harrell's c-index and Hosmer-
Lemeshow analyses were used to test PRS discrimination and calibration. KaplaneMeier curve for risk
groups as described in the original study were displayed.
Results: A total of 355 patients with 174 deaths during the follow-up period (median¼ 41.7 months, IQR
32.8e50.6) were included. The median PRS value was 14.7 (IQR 10.7e20.6), with normal distribution
across the cohort. A Cox regression on PRS covariates found coefficients similar to those of the derivation
cohort, except for tumor size. Measures of discrimination estimated by Harrell's c-index was 0.61(95%
CI:0.56e0.67) and Hosmer-Lemeshow p¼ 0.175. The Kaplan-Meyer estimation showed reasonable
discrimination across risk groups, with 5years survival rate ranging from 20.1% to 0%.esented as a poster to the ACHBT-SFCD 2018 French congresses in Paris, France. Moreover, it was accepted as oral
s in Amsterdam, June 2019.
ansplantation Surgery Hôpital de la PitieeSalpêtriere, Assistance Publique-Hôpitaux de Paris, France.
).
on for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
R. Brustia et al. / European Journal of Surgical Oncology 46 (2020) 560e571 561Conclusion: In this external validation cohort, the PRS had mild discrimination and poor calibration
performance, similarly to the original publication. Nevertheless, its ability to identify different classes of
risk is clinically useful, for a better tailoring of a therapeutic strategy.
© 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
Intrahepatic cholangiocarcinoma (ICC) represents less than 10%
of all cholangiocarcinomas [1], with age-adjusted incidence
increasing in Western countries from 2.1 to 3.3 per 100000 [1,2].
The highly desmoplastic nature of ICC and genetic heterogeneity
contribute to its therapeutic resistance and poor prognosis [1,3].
Surgery represents the mainstay of curative treatment [4], with 5
years overall survival (OS) varying from 15% to 50% [3,5e7]. Despite,
given the high recurrence and the considerable morbidity rate, it is
unclear which patients could really benefit of surgical resection
[8e11].
Preoperative prediction models are used to estimate the prob-
ability of developing a particular outcome, stratifying patients ac-
cording to their risk to develop e for example - recurrence or death
from disease. Albeit their purpose is not to replace clinical judg-
ment, they have a clear role in supporting clinical decisions. Evi-
dence exists that their use provides more accurate estimates of risk
as compared to subjective predictions [12]. To support its broad
adoption, a clinical prediction model should be confirmed by
applying this model to an independent, “external”, dataset [13].
The aim of this study was to realize an external validation of a
preoperative risk score (PRS) predicting long-term outcomes of
patients treated for ICC, published by Sasaki et al. in 2018 [14].
We decided to select this score for validation because its
composition is based on four easy-to-use clinical parameters, sys-
tematically collected in any standard preoperative workout: tumor
size, carbohydrate antigen 19-9 (CA19-9) level, neutrophil-to-
lymphocyte ratio (NLR) and albumin. Moreover, if validated, this
PRS could be clinically relevant to help clinicians to draw tailored
strategies, weighting the potential harms of extended surgery
against the predicted prognosis.Methods
This study was an international, multicenter independent
cohort study for the external validation of a published ICC PRS [14].
The study was designed in February 2018: eleven international,
tertiary hepato-pancreatic-biliary (HPB) centers from Europe,
South America and Japanwere proposed to participate to the study
(complete list in Supp. Material). The study was approved by the
ethical committee of each Institution.
The PRS derivation cohort in the original study [14] included
269 patients who underwent curative-intent liver surgery (LS) for
ICC between 1990 and 2015 at 16 HPB centers.
To avoid any historical bias in the external validation cohort due
to the evolution of clinical and surgical management, we decided to
start inclusions of patients treated by LS from January 2001 up to
June 2018, with a minimum follow-up period per patient of 6
months (so up-to December 2018).
Reporting of this study was based on the “transparent reporting
of a multivariable prediction model for individual prognosis or
diagnosis” (TRIPOD) Statement and guidelines [15] (supple-
mentary_table_TRIPOD_1). More details for the Methods section in
Supplementary_Material_2.Study endpoints
The primary endpoint was overall patient survival, to validate
the predictive discrimination value of the PRS score.
The secondary endpoints were the definition of preoperative,
intraoperative and postoperative variables predicting survival.
Eligibility criteria
Adult patients (>18 y old) undergoing LS for ICC confirmed on
the pathology report, were eligible to be included in the study
cohort. The definition for LS included any procedure requiring the
resection of one or more liver segments, by either an open or
laparoscopic approach.
Patients undergoing local ablation procedures (radiofrequency
or microwave ablation) were considered for inclusion only if this
was part of a surgical strategy including the removal of at least one
liver segment during the same intervention.
Patients who underwent R2 resection were excluded from the
study, as well as patients for whom data allowing the calculation of
the PRS were not available or who were lost to follow-up.
Primary outcome
To validate the PRS score, the primary outcome variables
collected were the event (death) and time until the event (OS), this
latter defined as the time from surgical intervention to death or to
date of last follow-up.
PRS survival prediction model
The prognostic variables in the PRS multivariable Cox model
were preoperative albumin level, preoperative leucocytes and
neutrophils, CA 19-9 level and tumor diameter (cm) on the pre-
operative CT-scan [14]. With this PRS, the predicted risk of OS at 5
years as well as the predicted median OS in months can be calcu-
lated preoperatively for each patient. In the original study the PRS
was divided in five class of risk: low-risk patients with a PRS be-
tween 0 and 5 had a predicted 5y OS of 66.1% (median OS “not
reached”) while high-risk patients with PRS >40 had a predicted 5y
OS of 0% (median OS 5.1 months).
In this external validation study, we used the same four candi-
date prognostic variables defined in the original study.
Variables
The preoperative, intraoperative and postoperative variables
used in this study were retrieved from each single center pro-
spective or retrospective database. As far as possible, we used the
same definitions, scoring system, tables and figures organization as
in the original article [14].
Data from different Centers were harmonized and merged in a
single dataset for analysis. Each patient was de-identified and
assigned to an anonymized alphanumeric code. Datawere regularly
entered in a digital worksheet-database, hosted on a secured
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The quality of data management was compliant to the reference
methodology on personal data processing and protection (MR003),
as stated by French data protection authority (Commission Nationale
de l'Informatique et des Libertes, CNIL n2208386 v 0).
Sample size
The only formal recommendation in the context of an external
validation study is that a substantial validation sample is required
[13]. For this reason, we decided to include at least the same
number of patients used in the derivation cohort (n¼ 269): at the
end of the accrual period, n¼ 355 patients were included.
However, there is no single rule based on predictor parameters
that would guarantee an accurate estimation of logistic regression
parameters. When dealing with mortality in external validation
studies, a minimum number of 100 events has been recommended,
or aminimumof 10 events per predictor parameter for proportional
hazards regression [16,17] per variable. Nevertheless the “10 event
rule” has generated much debate, with Authors suggesting
numbers ranging from <10 up to 50 [18].
A complex statistical approach to fix this issue has been pro-
posed by Riley et al. [18], suggesting that the minimum number of
events per predictor parameter should be calculated to meet the
following criteria:
- small optimism in predictor effect estimates as defined by a
global shrinkage factor of 0.9.
- small absolute difference of 0.05 in the model's apparent and
adjusted Nagelkerke's R2.
- precise estimation of the overall risk in the population.
Based on the data from the original publication from Sasaki et al.
[14], and according to these steps, we calculated that the number of
event per predictor should be 6.15. We observed 174 deaths in the
external validation cohort, corresponding to 43.5 events per pre-
dictor parameter, satisfying the above reported calculation.
Missing data
No multiple imputation was used.
Statistical analysis methods
All analyses were performed using data from the external vali-
dation cohort, and the results were compared to those from the
original derivation cohort [14]. In particular, to calculate the PRS
score we used the same predictors described in the original deri-
vation cohort:
[9þ (2.79 albumin)þ (0.50 NLR)þ (2.81 natural logarithm
CA 19-9) þ (1.12  tumor size)]. All variables with p < 0.05 were
considered statistically significant.
Descriptive statistics
Categorical (qualitative) variables are reported as percentages,
while quantitative continuous variables are summarized as means
and standard deviation (SD) or median (range) for discrete vari-
ables, as appropriate. A KaplaneMeier curve for the entire external
validation cohort was created through survfit and ggsurvplot
functions from survminer and survival packages.
Primary objective¼ external validation of PRS
The external validation of the PRS survival prediction model
followed the methods described by Royston et al. [13]. Regression on the Prognostic Index
The Prognostic Index (PI) is the weighted sum of the prognostic
variables, where the weights are the regression coefficients from
the derivation cohort. A Cox proportional hazards model was fit
with the PI as the only prognostic variable. A calibration slope
smaller than 1 indicates suboptimal discrimination. A score test
was performed to test for if the slope was significantly different
from 1.
 Model misspecification/fit
Model fit was defined as the agreement of the regression co-
efficients between the derivation and validation cohorts. It was
assessed by fitting a Cox model that included the prognostic vari-
ables and the PI (using the original coefficients from the derivation
cohort) as an ‘offset’ variable. The model is considered to fit well if
the regression coefficients for the prognostic variables were not
statistically significantly different from 0. This was tested jointly for
significance using a pooled likelihood ratio (LR) test from each
multiple imputation.
 Measures of discrimination
To determine the discriminative ability of the PRS survival
prediction model, the Harrell's c-index of concordance was calcu-
lated in the validation cohort. Harrell's c-index reflects the pro-
portion of all patient pairs in which the predicted and observed
outcomes are accordant. An index value close to 1 is considered to
reflect good performance of the model. The graphical expression
was plot through a ROC curve from the pROC package.
 Measures of Calibration
Calibration is the agreement between prediction from the
model and observed outcomes, reflecting the predictive accuracy of
the model. The Hosmer-Lemeshow goodness of fit test can be
calculated through the gof function from survMisc library, and
represented through a calibration plot [12].
 KaplaneMeier curve for risk groups
KaplaneMeier curves for OS were created with five strata cor-
responding to the risk groups from the original study, in order to
allow a visual evaluation of the discriminative ability of the PRS
prediction model. Moreover, a comparison of KaplaneMeier deri-
vation and validation plots offers a rough assessment of the model
calibration [13].
Secondary objectives¼ definition of preoperative, intra-
operative and postoperative variables predicting survival.
Unadjusted hazard ratios (HRs) and 95% confidence intervals
(95% CI) were calculated for pre-, per- and postoperative variables
associated with death, by a Cox proportional hazard regression
analysis. Variables with a p value> than 0.1 were entered in a
multivariate Cox model to identify factors independently associated
with death. The finalmodelwill express the adjustedHRs and 95%CI.Statistical software
Datamanaging and statistical evaluationwere performedwith R
software (version 3.5.2 and following. The R Foundation for Sta-
tistical Computing. www.cran.r-project.org, Vienna, Austria).
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Participants
During the seventeen years' study period (2001e2018), 355
patients undergoing to LS for ICC in 11 participating centers were
included and represented the study cohort. Among them 52%
(n¼ 185) were male with a median age of 68.0 (60.0e74) years.
Obesity (BMI>30 kg/m2) was observed in 17% of patients (n¼ 60)
and diabetes, metabolic syndrome, and cirrhosis in 21% (n¼ 72),
20% (n¼ 57) and 10% (n¼ 32) of them, respectively. The median
values of the four PRS predictors were 4.07 g/dL (3.70e4.30) serum
albumin level, 2.5 (1.7e3.7) NLR, 30.0 IU/mL (10.9e106.5) serum
carbohydrate antigen 19-9 level and 5.0 cm (3.4e8.0) for the
maximum tumor diameter. Major hepatectomywas required in 69%
(n¼ 170) of patients, with a laparoscopic approach in 12% (n¼ 43)
of cases. An associated procedure was required in 22% (n¼ 58) of
patients, as biliary or vascular reconstruction: 16% (n¼ 42) and 7%
(n¼ 19), respectively. One, three, five and ten year's survival rate
was 86%, 53%, 40% and 20%, respectively (supp_Fig. 1). The mean
overall and disease-free survival for the entire cohort was 63.3± 4.0
and 56.4± 4.2 months, respectively.
More details on Table 1. In order to highlight the role of each
predictor parameter of the PRS, in Table 2 are detailed their dis-
tribution per each PRS risk class, among the group of patients
experiencing death (event).Primary objective¼ external validation of PRS
The distribution of the PRS in the validation cohort follows a
Normal distribution (One-sample Kolmogorov-Smirnov test
D¼ 0.10357, p-value¼ 0.001513). The median observed PRS value
in the original derivation cohort [14] and external validation cohort
was 17 and 14.685 (IQR 10.722e20.634) (Fig. 1), respectively.Fig. 1. The distribution of the preoperative risk scores (PRS) was normally distributed over
with a median PRS value of 14.7. The vertical dotted line shows the PRS mean (16.6± 9.9) and
observed in the cohort.Regression on the Prognostic Index
The observed slope in the Cox proportional hazards model on
the PRS in the external validation cohort was 0.02 (p¼ 0.01), sug-
gesting a mild discrimination of the model (Table 3).Model misspecification/fit
A Cox regression on the predictors covariates of the original PRS
in the external validation cohort found similar coefficients, except
for tumor size: 0.01324, 95%CI(0.995e1.0319)p¼ 0.1542 versus
0.112, 95%CI(1.06e1.18) p¼ 0.001 in the orginal derivation cohort
[14]. (Table 3).Measures of discrimination
In the original study the calculated c-index for PRS was 0.69 95%
CI(0.65e0.74). In this external validation cohort, Harrell's c-index
was 0.61 95%CI(0.56e0.67), which reflects modest discrimination,
as well as in the original study (Table 3 and Fig. 2).Measures of calibration
The Hosmer-Lemeshow goodness of fit test found 173.9 ex-
pected deaths against 174 deaths observed (p¼ 0.175) (Table 3;
Calibration plot of the observed and predicted death depending on
the severity of the PRS available on supp_fig_ 2).KaplaneMeier curves for risk groups
Fig. 3 displays the KaplaneMeier survival estimation for the
validation cohort, with the five strata corresponding to the PRS risk
groups as described in the derivation cohort. Grossly, apart the first
6e12months during which some overlap among PRS group 2 to 5 is
observed, the five curves are well separated, similarly to what is
observed in the derivation cohort.the external derivation cohort (One-sample Kolmogorov-Smirnov test, D¼ 0.099055)
the red line the theoretical Normal distribution. Two PRS outliers (69.2 and 107.8) were
Table 1
Characteristics of the external validation cohort.
PRS 1 PRS 2 PRS 3 PRS 4 PRS 5 Overall
(n¼ 72) (n¼ 183) (n¼ 73) (n¼ 22) (n¼ 5) (n¼ 355)
PREOPERATIVE CHARACTERISTICS
Gender
F 30 (41.7%) 89 (48.6%) 38 (52.1%) 9 (40.9%) 4 (80.0%) 170 (47.9%)
M 42 (58.3%) 94 (51.4%) 35 (47.9%) 13 (59.1%) 1 (20.0%) 185 (52.1%)
Age, years
Mean (SD) 67.7 (9.11) 64.8 (11.7) 67.9 (9.53) 64.3 (8.79) 74.3 (3.68) 66.2 (10.6)
Median [Min, Max] 70.0 [46.0, 86.5] 66.0 [32.0, 84.0] 69.0 [43.0, 84.0] 65.5 [43.0, 80.0] 74.0 [69.0, 79.0] 68.0 [32.0, 86.5]
BMI, Kg/m2
Mean (SD) 26.3 (6.05) 24.3 (5.60) 25.2 (6.37) 26.9 (5.19) 24.8 (1.34) 25.0 (5.85)
Median [Min, Max] 26.7 [13.4, 43.0] 24.0 [10.5, 45.6] 24.7 [7.72, 43.0] 25.6 [19.3, 39.0] 25.3 [23.0, 26.0] 24.6 [7.72, 45.6]
BMI, class
<18 4 (5.6%) 19 (10.4%) 7 (9.6%) 0 (0%) 0 (0%) 30 (8.5%)
18_25 29 (40.3%) 89 (48.6%) 36 (49.3%) 10 (45.5%) 3 (60.0%) 167 (47.0%)
26_30 19 (26.4%) 49 (26.8%) 14 (19.2%) 5 (22.7%) 2 (40.0%) 89 (25.1%)
31_35 13 (18.1%) 16 (8.7%) 11 (15.1%) 5 (22.7%) 0 (0%) 45 (12.7%)
>35 4 (5.6%) 4 (2.2%) 4 (5.5%) 1 (4.5%) 0 (0%) 13 (3.7%)
Obesity (BMI>30)
0 52 (72.2%) 157 (85.8%) 57 (78.1%) 15 (68.2%) 5 (100%) 286 (80.6%)
1 18 (25.0%) 20 (10.9%) 15 (20.5%) 7 (31.8%) 0 (0%) 60 (16.9%)
Diabetes
0 54 (75.0%) 143 (78.1%) 58 (79.5%) 17 (77.3%) 4 (80.0%) 276 (77.7%)
1 17 (23.6%) 35 (19.1%) 14 (19.2%) 5 (22.7%) 1 (20.0%) 72 (20.3%)
Arterial Hypertension
0 39 (54.2%) 102 (55.7%) 36 (49.3%) 10 (45.5%) 1 (20.0%) 188 (53.0%)
1 33 (45.8%) 76 (41.5%) 35 (47.9%) 12 (54.5%) 4 (80.0%) 160 (45.1%)
Dyslipidemia
0 40 (55.6%) 103 (56.3%) 44 (60.3%) 15 (68.2%) 3 (60.0%) 205 (57.7%)
1 19 (26.4%) 21 (11.5%) 11 (15.1%) 4 (18.2%) 2 (40.0%) 57 (16.1%)
Metabolic syndrome
0 46 (63.9%) 121 (66.1%) 47 (64.4%) 14 (63.6%) 4 (80.0%) 232 (65.4%)
1 20 (27.8%) 20 (10.9%) 11 (15.1%) 5 (22.7%) 1 (20.0%) 57 (16.1%)
Viral Hepatitis
0 56 (77.8%) 147 (80.3%) 60 (82.2%) 20 (90.9%) 4 (80.0%) 287 (80.8%)
1 16 (22.2%) 33 (18.0%) 12 (16.4%) 2 (9.1%) 1 (20.0%) 64 (18.0%)
HIV
0 58 (80.6%) 125 (68.3%) 57 (78.1%) 19 (86.4%) 5 (100%) 264 (74.4%)
1 1 (1.4%) 1 (0.5%) 0 (0%) 0 (0%) 0 (0%) 2 (0.6%)
Alcohol
0 51 (70.8%) 135 (73.8%) 59 (80.8%) 15 (68.2%) 4 (80.0%) 264 (74.4%)
1 21 (29.2%) 44 (24.0%) 12 (16.4%) 7 (31.8%) 1 (20.0%) 85 (23.9%)
Biliary disease
0 58 (80.6%) 123 (67.2%) 51 (69.9%) 17 (77.3%) 5 (100%) 254 (71.5%)
1 1 (1.4%) 4 (2.2%) 4 (5.5%) 2 (9.1%) 0 (0%) 11 (3.1%)
Digestive disease
0 59 (81.9%) 122 (66.7%) 51 (69.9%) 18 (81.8%) 5 (100%) 255 (71.8%)
1 0 (0%) 5 (2.7%) 4 (5.5%) 1 (4.5%) 0 (0%) 10 (2.8%)
Hemochromatosis
0 58 (80.6%) 122 (66.7%) 54 (74.0%) 18 (81.8%) 5 (100%) 257 (72.4%)
1 1 (1.4%) 4 (2.2%) 1 (1.4%) 1 (4.5%) 0 (0%) 7 (2.0%)
Smoke
0 43 (59.7%) 83 (45.4%) 38 (52.1%) 16 (72.7%) 5 (100%) 185 (52.1%)
1 15 (20.8%) 40 (21.9%) 17 (23.3%) 3 (13.6%) 0 (0%) 75 (21.1%)
ASA score
I 3 (4.2%) 7 (3.8%) 4 (5.5%) 2 (9.1%) 0 (0%) 16 (4.5%)
II 30 (41.7%) 63 (34.4%) 29 (39.7%) 9 (40.9%) 2 (40.0%) 133 (37.5%)
III 20 (27.8%) 39 (21.3%) 13 (17.8%) 5 (22.7%) 2 (40.0%) 79 (22.3%)
IV 2 (2.8%) 6 (3.3%) 4 (5.5%) 0 (0%) 0 (0%) 12 (3.4%)
Weight loss
0 43 (59.7%) 72 (39.3%) 30 (41.1%) 10 (45.5%) 2 (40.0%) 157 (44.2%)
1 4 (5.6%) 22 (12.0%) 14 (19.2%) 5 (22.7%) 0 (0%) 45 (12.7%)
Preoperative PVE
0 55 (76.4%) 114 (62.3%) 52 (71.2%) 18 (81.8%) 3 (60.0%) 242 (68.2%)
1 4 (5.6%) 12 (6.6%) 5 (6.8%) 1 (4.5%) 1 (20.0%) 23 (6.5%)
Preoperative Chemotherapy
0 54 (75.0%) 113 (61.7%) 53 (72.6%) 19 (86.4%) 5 (100%) 244 (68.7%)
1 4 (5.6%) 15 (8.2%) 4 (5.5%) 0 (0%) 0 (0%) 23 (6.5%)
Serum albumin level, g/dL
Mean (SD) 4.18 (0.443) 4.02 (0.537) 3.83 (0.571) 3.75 (0.553) 3.62 (0.680) 3.99 (0.543)
Median [Min, Max] 4.20 [3.10, 5.50] 4.10 [2.50, 7.20] 3.95 [2.00, 5.30] 3.75 [2.80, 4.90] 3.60 [3.00, 4.70] 4.07 [2.00, 7.20]
Neutrophil to lymphocyte ration
Mean (SD) 2.50 (1.83) 2.85 (1.83) 3.72 (2.29) 4.52 (5.71) 15.6 (22.3) 3.24 (3.67)
Median [Min, Max] 2.22 [0.567, 12.1] 2.31 [0.436, 13.1] 3.37 [0.512, 14.6] 3.04 [0.705, 28.5] 5.20 [0.858, 54.5] 2.53 [0.436, 54.5]
Serum carbohydrate antigen 19e9 level, IU/mL
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Table 1 (continued )
PRS 1 PRS 2 PRS 3 PRS 4 PRS 5 Overall
(n¼ 72) (n¼ 183) (n¼ 73) (n¼ 22) (n¼ 5) (n¼ 355)
Mean (SD) 7.41 (8.09) 61.2 (97.5) 715 (1430) 12800 (14900) 3610 (4580) 1020 (4820)
Median [Min, Max] 2.10 [0.200, 25.5] 30.4 [1.00, 805] 142 [5.00, 8110] 5580 [10.7, 50000] 1800 [28.0, 10900] 30.0 [0.200, 50000]
Maximum diameter of the tumor, cm
Mean (SD) 3.95 (1.93) 5.14 (2.55) 7.78 (3.81) 9.94 (6.20) 30.8 (33.7) 6.10 (5.80)
Median [Min, Max] 3.50 [0.800, 10.4] 4.80 [1.00, 13.0] 8.00 [1.30, 16.0] 8.00 [4.00, 27.0] 16.0 [7.50, 90.0] 5.00 [0.800, 90.0]
Preoperative risk score (PRS)
Mean (SD) 6.50 (2.84) 14.4 (2.85) 23.9 (2.93) 34.0 (2.13) 60.1 (29.3) 16.6 (9.86)
Median [Min, Max] 7.18 [-1.09, 9.94] 14.0 [8.08, 20.5] 22.9 [20.0, 29.7] 34.6 [30.2, 37.0] 41.8 [40.3, 108] 14.7 [-1.09, 108]
PERI OPERATIVE CHARACTERISTICS
Surgical approach
Laparoscopy 18 (25.0%) 20 (10.9%) 5 (6.8%) 0 (0%) 0 (0%) 43 (12.1%)
Open 54 (75.0%) 163 (89.1%) 68 (93.2%) 22 (100%) 5 (100%) 312 (87.9%)
Conversion to open
0 14 (19.4%) 16 (8.7%) 2 (2.7%) 0 (0%) 0 (0%) 32 (9.0%)
1 3 (4.2%) 1 (0.5%) 2 (2.7%) 0 (0%) 0 (0%) 6 (1.7%)
Number of removed segments
I 11 (15.3%) 8 (4.4%) 1 (1.4%) 1 (4.5%) 0 (0%) 21 (5.9%)
II 14 (19.4%) 24 (13.1%) 5 (6.8%) 2 (9.1%) 0 (0%) 45 (12.7%)
III 8 (11.1%) 21 (11.5%) 6 (8.2%) 2 (9.1%) 2 (40.0%) 39 (11.0%)
IV 8 (11.1%) 35 (19.1%) 21 (28.8%) 8 (36.4%) 1 (20.0%) 73 (20.6%)
V 7 (9.7%) 16 (8.7%) 8 (11.0%) 2 (9.1%) 0 (0%) 33 (9.3%)
VI 4 (5.6%) 12 (6.6%) 13 (17.8%) 3 (13.6%) 1 (20.0%) 33 (9.3%)
Major hepatectomy
0 29 (40.3%) 37 (20.2%) 6 (8.2%) 3 (13.6%) 1 (20.0%) 76 (21.4%)
1 24 (33.3%) 80 (43.7%) 48 (65.8%) 15 (68.2%) 3 (60.0%) 170 (47.9%)
Assocated procedures
0 55 (76.4%) 105 (57.4%) 35 (47.9%) 12 (54.5%) 4 (80.0%) 211 (59.4%)
1 4 (5.6%) 24 (13.1%) 22 (30.1%) 7 (31.8%) 1 (20.0%) 58 (16.3%)
Biliary procedures
0 57 (79.2%) 112 (61.2%) 39 (53.4%) 14 (63.6%) 3 (60.0%) 225 (63.4%)
1 2 (2.8%) 16 (8.7%) 18 (24.7%) 5 (22.7%) 1 (20.0%) 42 (11.8%)
Vascular procedures
0 56 (77.8%) 122 (66.7%) 52 (71.2%) 14 (63.6%) 4 (80.0%) 248 (69.9%)
1 3 (4.2%) 6 (3.3%) 5 (6.8%) 5 (22.7%) 0 (0%) 19 (5.4%)
Total vascular exclusio
0 58 (80.6%) 120 (65.6%) 52 (71.2%) 17 (77.3%) 4 (80.0%) 251 (70.7%)
1 1 (1.4%) 8 (4.4%) 5 (6.8%) 2 (9.1%) 0 (0%) 16 (4.5%)
Extracorporeal circulation
0 58 (80.6%) 128 (69.9%) 57 (78.1%) 18 (81.8%) 4 (80.0%) 265 (74.6%)
1 1 (1.4%) 0 (0%) 0 (0%) 1 (4.5%) 0 (0%) 2 (0.6%)
Liver cooling
0 58 (80.6%) 128 (69.9%) 56 (76.7%) 18 (81.8%) 4 (80.0%) 264 (74.4%)
1 1 (1.4%) 0 (0%) 1 (1.4%) 1 (4.5%) 0 (0%) 3 (0.8%)
Blood transfusion
0 43 (59.7%) 88 (48.1%) 33 (45.2%) 9 (40.9%) 2 (40.0%) 175 (49.3%)
1 7 (9.7%) 20 (10.9%) 13 (17.8%) 6 (27.3%) 1 (20.0%) 47 (13.2%)
N RBC
0 43 (59.7%) 88 (48.1%) 33 (45.2%) 8 (36.4%) 2 (40.0%) 174 (49.0%)
1 0 (0%) 2 (1.1%) 3 (4.1%) 0 (0%) 1 (20.0%) 6 (1.7%)
2 6 (8.3%) 10 (5.5%) 6 (8.2%) 2 (9.1%) 0 (0%) 24 (6.8%)
3 0 (0%) 2 (1.1%) 0 (0%) 1 (4.5%) 0 (0%) 3 (0.8%)
4 1 (1.4%) 3 (1.6%) 1 (1.4%) 1 (4.5%) 0 (0%) 6 (1.7%)
5 0 (0%) 0 (0%) 0 (0%) 1 (4.5%) 0 (0%) 1 (0.3%)
6 0 (0%) 1 (0.5%) 1 (1.4%) 1 (4.5%) 0 (0%) 3 (0.8%)
8 0 (0%) 1 (0.5%) 1 (1.4%) 0 (0%) 0 (0%) 2 (0.6%)
Blood loss, mL
Mean (SD) 440 (767) 631 (837) 621 (553) 2030 (5150) 222 (38.7) 676 (1500)
Median [Min, Max] 250 [0.00, 5400] 445 [0.00, 6000] 500 [20.0, 2990] 586 [0.00, 21700] 200 [200, 267] 400 [0.00, 21700]
Blood loss, class
0_200 23 (31.9%) 36 (19.7%) 14 (19.2%) 4 (18.2%) 2 (40.0%) 79 (22.3%)
200_400 11 (15.3%) 32 (17.5%) 10 (13.7%) 4 (18.2%) 1 (20.0%) 58 (16.3%)
400_600 10 (13.9%) 25 (13.7%) 12 (16.4%) 2 (9.1%) 0 (0%) 49 (13.8%)
600_800 2 (2.8%) 19 (10.4%) 8 (11.0%) 1 (4.5%) 0 (0%) 30 (8.5%)
>800 6 (8.3%) 28 (15.3%) 14 (19.2%) 6 (27.3%) 0 (0%) 54 (15.2%)
PATHOLOGY CHARACTERISTICS
Mass forming type
0 2 (2.8%) 14 (7.7%) 2 (2.7%) 2 (9.1%) 0 (0%) 20 (5.6%)
1 45 (62.5%) 94 (51.4%) 52 (71.2%) 16 (72.7%) 4 (80.0%) 211 (59.4%)
Maximum diameter of the tumor, mm
Mean (SD) 41.1 (21.1) 52.0 (25.5) 74.7 (39.0) 102 (60.6) 100 (57.2) 58.2 (35.6)
Median [Min, Max] 35.0 [8.00, 104] 50.0 [10.0, 140] 80.0 [10.0, 160] 80.0 [40.0, 270] 85.0 [25.0, 160] 50.0 [8.00, 270]
Diameter of the tumor, classes, cm
0_1 1 (1.4%) 2 (1.1%) 1 (1.4%) 0 (0%) 0 (0%) 4 (1.1%)
(continued on next page)
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Table 1 (continued )
PRS 1 PRS 2 PRS 3 PRS 4 PRS 5 Overall
(n¼ 72) (n¼ 183) (n¼ 73) (n¼ 22) (n¼ 5) (n¼ 355)
1_2 8 (11.1%) 15 (8.2%) 5 (6.8%) 0 (0%) 0 (0%) 28 (7.9%)
2_3 19 (26.4%) 28 (15.3%) 7 (9.6%) 0 (0%) 1 (20.0%) 55 (15.5%)
3_4 13 (18.1%) 31 (16.9%) 8 (11.0%) 2 (9.1%) 0 (0%) 54 (15.2%)
4_5 12 (16.7%) 23 (12.6%) 5 (6.8%) 0 (0%) 0 (0%) 40 (11.3%)
5_6 7 (9.7%) 24 (13.1%) 3 (4.1%) 3 (13.6%) 0 (0%) 37 (10.4%)
6_7 5 (6.9%) 21 (11.5%) 4 (5.5%) 4 (18.2%) 0 (0%) 34 (9.6%)
7_8 2 (2.8%) 16 (8.7%) 9 (12.3%) 3 (13.6%) 1 (20.0%) 31 (8.7%)
>8 4 (5.6%) 22 (12.0%) 31 (42.5%) 10 (45.5%) 3 (60.0%) 70 (19.7%)
Number of lesions
1 49 (68.1%) 99 (54.1%) 50 (68.5%) 15 (68.2%) 3 (60.0%) 216 (60.8%)
2 2 (2.8%) 9 (4.9%) 2 (2.7%) 1 (4.5%) 1 (20.0%) 15 (4.2%)
3 1 (1.4%) 7 (3.8%) 1 (1.4%) 0 (0%) 0 (0%) 9 (2.5%)
4 0 (0%) 0 (0%) 1 (1.4%) 1 (4.5%) 0 (0%) 2 (0.6%)
5 0 (0%) 1 (0.5%) 0 (0%) 0 (0%) 0 (0%) 1 (0.3%)
6 1 (1.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.3%)
12 0 (0%) 0 (0%) 0 (0%) 1 (4.5%) 0 (0%) 1 (0.3%)
Single or multiple nodules
Multiple 4 (5.6%) 18 (9.8%) 4 (5.5%) 3 (13.6%) 1 (20.0%) 30 (8.5%)
Single 49 (68.1%) 99 (54.1%) 50 (68.5%) 15 (68.2%) 3 (60.0%) 216 (60.8%)
Pathology-proven satellite lesions
0 45 (62.5%) 86 (47.0%) 33 (45.2%) 9 (40.9%) 3 (60.0%) 176 (49.6%)
1 8 (11.1%) 31 (16.9%) 21 (28.8%) 9 (40.9%) 1 (20.0%) 70 (19.7%)
American Joint Committee on Cancer
Tumor stage (T)
I 27 (37.5%) 35 (19.1%) 14 (19.2%) 5 (22.7%) 1 (20.0%) 82 (23.1%)
II 32 (44.4%) 93 (50.8%) 39 (53.4%) 7 (31.8%) 3 (60.0%) 174 (49.0%)
III 9 (12.5%) 39 (21.3%) 14 (19.2%) 6 (27.3%) 0 (0%) 68 (19.2%)
IV 4 (5.6%) 14 (7.7%) 6 (8.2%) 4 (18.2%) 1 (20.0%) 29 (8.2%)
Lymph node status (N)
N0 40 (55.6%) 114 (62.3%) 37 (50.7%) 11 (50.0%) 4 (80.0%) 206 (58.0%)
I 7 (9.7%) 37 (20.2%) 28 (38.4%) 7 (31.8%) 0 (0%) 79 (22.3%)
X 25 (34.7%) 32 (17.5%) 8 (11.0%) 4 (18.2%) 1 (20.0%) 70 (19.7%)
Metastasis (M)
0 52 (72.2%) 139 (76.0%) 59 (80.8%) 17 (77.3%) 3 (60.0%) 270 (76.1%)
I 0 (0%) 4 (2.2%) 2 (2.7%) 0 (0%) 0 (0%) 6 (1.7%)
Histologic differentiation
Well 9 (12.5%) 17 (9.3%) 4 (5.5%) 4 (18.2%) 1 (20.0%) 35 (9.9%)
Moderate 34 (47.2%) 61 (33.3%) 27 (37.0%) 11 (50.0%) 2 (40.0%) 135 (38.0%)
Poor 15 (20.8%) 50 (27.3%) 26 (35.6%) 4 (18.2%) 2 (40.0%) 97 (27.3%)
Biliary invasion
0 35 (48.6%) 73 (39.9%) 31 (42.5%) 7 (31.8%) 3 (60.0%) 149 (42.0%)
1 9 (12.5%) 23 (12.6%) 15 (20.5%) 6 (27.3%) 0 (0%) 53 (14.9%)
Vascular invasion
0 24 (33.3%) 57 (31.1%) 16 (21.9%) 5 (22.7%) 1 (20.0%) 103 (29.0%)
1 32 (44.4%) 68 (37.2%) 39 (53.4%) 13 (59.1%) 3 (60.0%) 155 (43.7%)
Nervous engainment
0 37 (51.4%) 78 (42.6%) 28 (38.4%) 6 (27.3%) 3 (60.0%) 152 (42.8%)
1 17 (23.6%) 38 (20.8%) 28 (38.4%) 12 (54.5%) 1 (20.0%) 96 (27.0%)
Adjacent liver
Fibrosis (F)
0 31 (43.1%) 79 (43.2%) 37 (50.7%) 14 (63.6%) 4 (80.0%) 165 (46.5%)
I 19 (26.4%) 41 (22.4%) 22 (30.1%) 3 (13.6%) 0 (0%) 85 (23.9%)
II 1 (1.4%) 12 (6.6%) 2 (2.7%) 0 (0%) 0 (0%) 15 (4.2%)
III 3 (4.2%) 8 (4.4%) 1 (1.4%) 2 (9.1%) 0 (0%) 14 (3.9%)
IV (Cirrhosis) 9 (12.5%) 18 (9.8%) 3 (4.1%) 2 (9.1%) 0 (0%) 32 (9.0%)
Steatosis
0 24 (33.3%) 76 (41.5%) 30 (41.1%) 13 (59.1%) 3 (60.0%) 146 (41.1%)
1 27 (37.5%) 37 (20.2%) 24 (32.9%) 5 (22.7%) 1 (20.0%) 94 (26.5%)
Resection margin
R 0 58 (80.6%) 153 (83.6%) 58 (79.5%) 16 (72.7%) 3 (60.0%) 288 (81.1%)
R 1 14 (19.4%) 28 (15.3%) 14 (19.2%) 5 (22.7%) 1 (20.0%) 62 (17.5%)
Resection margin, mm
Mean (SD) 6.57 (8.72) 7.71 (11.2) 7.62 (10.9) 2.87 (4.21) 4.00 (4.08) 7.02 (10.2)
Median [Min, Max] 3.00 [0.00, 40.0] 5.00 [0.00, 90.0] 3.00 [0.00, 50.0] 0.900 [0.00, 15.0] 4.00 [0.00, 8.00] 4.00 [0.00, 90.0]
Missing 19 (26.4%) 67 (36.6%) 19 (26.0%) 4 (18.2%) 1 (20.0%) 110 (31.0%)
Resection margin, mm classes
0_5 32 (44.4%) 71 (38.8%) 35 (47.9%) 15 (68.2%) 2 (40.0%) 155 (43.7%)
5_10 11 (15.3%) 21 (11.5%) 8 (11.0%) 2 (9.1%) 2 (40.0%) 44 (12.4%)
10_15 4 (5.6%) 8 (4.4%) 4 (5.5%) 1 (4.5%) 0 (0%) 17 (4.8%)
15_20 2 (2.8%) 9 (4.9%) 2 (2.7%) 0 (0%) 0 (0%) 13 (3.7%)
>20 4 (5.6%) 7 (3.8%) 5 (6.8%) 0 (0%) 0 (0%) 16 (4.5%)
POSTOPERATIVE CHARACTERISTICS
Postoeprative complications
0 46 (63.9%) 101 (55.2%) 37 (50.7%) 6 (27.3%) 0 (0%) 190 (53.5%)
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Table 1 (continued )
PRS 1 PRS 2 PRS 3 PRS 4 PRS 5 Overall
(n¼ 72) (n¼ 183) (n¼ 73) (n¼ 22) (n¼ 5) (n¼ 355)
1 19 (26.4%) 62 (33.9%) 31 (42.5%) 14 (63.6%) 3 (60.0%) 129 (36.3%)
Clavien-Dindo
0 38 (52.8%) 66 (36.1%) 26 (35.6%) 4 (18.2%) 0 (0%) 134 (37.7%)
I 4 (5.6%) 10 (5.5%) 4 (5.5%) 2 (9.1%) 1 (20.0%) 21 (5.9%)
II 11 (15.3%) 30 (16.4%) 13 (17.8%) 5 (22.7%) 0 (0%) 59 (16.6%)
III 3 (4.2%) 18 (9.8%) 10 (13.7%) 5 (22.7%) 1 (20.0%) 37 (10.4%)
IV 0 (0%) 2 (1.1%) 1 (1.4%) 0 (0%) 1 (20.0%) 4 (1.1%)
V 1 (1.4%) 2 (1.1%) 3 (4.1%) 2 (9.1%) 0 (0%) 8 (2.3%)
ICU stay
Mean (SD) 1.00 (1.82) 1.63 (4.41) 2.45 (9.23) 1.40 (2.29) 1.50 (0.707) 1.66 (5.42)
Median [Min, Max] 0.00 [0.00, 7.00] 0.00 [0.00, 36.0] 0.00 [0.00, 63.0] 0.00 [0.00, 8.00] 1.50 [1.00, 2.00] 0.00 [0.00, 63.0]
Hospital stay
Mean (SD) 10.8 (8.84) 14.8 (14.8) 17.3 (19.4) 22.2 (18.4) 14.5 (3.42) 15.0 (15.4)
Median [Min, Max] 9.00 [3.00, 50.0] 10.0 [2.00, 114] 10.0 [3.00, 104] 16.0 [2.00, 73.0] 15.0 [10.0, 18.0] 10.0 [2.00, 114]
Missing 20 (27.8%) 68 (37.2%) 19 (26.0%) 4 (18.2%) 1 (20.0%) 112 (31.5%)
Postoperative chemotherapy
0 39 (54.2%) 84 (45.9%) 28 (38.4%) 11 (50.0%) 2 (40.0%) 164 (46.2%)
1 12 (16.7%) 31 (16.9%) 26 (35.6%) 6 (27.3%) 1 (20.0%) 76 (21.4%)
Recurrence
0 41 (56.9%) 71 (38.8%) 27 (37.0%) 7 (31.8%) 2 (40.0%) 148 (41.7%)
1 29 (40.3%) 101 (55.2%) 44 (60.3%) 15 (68.2%) 2 (40.0%) 191 (53.8%)
Disease free survival, moths
Mean (SD) 30.3 (30.6) 28.3 (31.3) 18.2 (20.5) 15.9 (24.7) 5.63 (5.04) 25.6 (29.1)
Median [Min, Max] 17.6 [0.100, 122] 14.5 [0.0667, 157] 11.6 [0.00, 107] 6.28 [0.0667, 92.0] 4.18 [1.71, 14.2] 13.6 [0.00, 157]
Death
0 53 (73.6%) 87 (47.5%) 30 (41.1%) 9 (40.9%) 2 (40.0%) 181 (51.0%)
1 19 (26.4%) 96 (52.5%) 43 (58.9%) 13 (59.1%) 3 (60.0%) 174 (49.0%)
Overall survival, moths
Mean (SD) 36.8 (29.8) 37.5 (31.7) 30.4 (25.9) 21.6 (23.7) 11.7 (13.1) 34.6 (29.9)
Median [Min, Max] 27.8 [0.100, 122] 27.9 [0.0667, 157] 24.4 [0.197, 131] 12.8 [0.0667, 92.0] 5.00 [2.43, 34.1] 25.9 [0.0667, 157]
F¼Female, M¼men, BMI¼ body mass index, HIV¼Human Immunodeficientia Virus, ASA¼American Society of Anesthesiologists, PVE¼Portal Vein Embolisation,
PRS¼Preoperative Risk Score, IU¼International Unit, RBC¼ Red Blood Cells, ICU¼Intensive care unit.
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and postoperative variables predicting survival
Preoperative variables (supplementary_Table 1)
A multivariate analysis was adjusted on history of digestive
disease, cirrhosis, weight loss, serum albumin level, NLR and CA 19-
9 preoperative value. After adjusting, NLR (HR 1.08, 95%CI(1.00,1.16)
p¼ 0.035) and preoperative CA 19-9 (HR 1.00, 95%CI(1.00,1.01)
p¼ 0.007) were independently associated with death.Peri and postoperative variables (supplementary_Table 2)
A multivariate analysis was adjusted on open/laparoscopic
approach, vascular reconstruction, blood loss (classes), blood
transfusion (Y/N), postoperative complication (Y/N), length ofTable 2
Distribution of each predictor parameter of the PRS among the patients experiencing de
PREDICTOR PARAMETER PRS 1 PRS 2 PRS 3
(n¼ 19) (n¼ 96) (n¼ 43)
Serum Albumin
Mean (SD) 4.14 (0.622) 4.02 (0.459) 3.72 (0.60
Median [Min, Max] 4.20 [3.10, 5.50] 4.10 [2.76, 5.00] 3.90 [2.00
NLR
Mean (SD) 2.61 (2.40) 2.91 (1.93) 3.81 (2.52
Median [Min, Max] 2.18 [0.995, 12.1] 2.30 [0.553, 13.1] 3.03 [0.68
CA 19e9 IU/mL
Mean (SD) 5.81 (6.30) 68.2 (110) 915 (1780
Median [Min, Max] 3.00 [0.600, 18.5] 30.0 [1.00, 805] 142 [10.0,
Tumor size (cm)
Mean (SD) 4.23 (1.80) 4.93 (2.55) 8.39 (3.58
Median [Min, Max] 3.50 [1.50, 8.20] 4.00 [1.00, 13.0] 9.00 [2.00
PRS¼Preoperative Risk Score, NLR¼ Neutrophil to lymphocyte ration, SD¼Strandard Devhospital stay and adjuvant chemotherapy. After adjusting only
blood transfusion (HR 1.90, 95%CI(1.01,3.59) p¼ 0.046) resulted
independently associated with death.Pathology variables (supplementary_Table 3)
A multivariate analysis was adjusted on the tumor size> 7 cm
(Y/N), presence of pathology-proven satellite lesions, T and N stage,
histologic differentiation, positive resection margin (R1), nervous
invasion, presence of steatosis or cirrhosis. After adjusting for
confounding variables the T IV stage (HR 2.57, 95%CI(1.027,6.441)
p¼ 0.044), NI status (HR 2.67, 95%CI(1.553,4.606) p¼ 0.001), posi-
tive resection margins (R1) (HR 2.12, 95%CI(1.205,3.740) p¼ 0.009)
and the presence of steatosis (HR 1.71, 95%CI(1.117,2.605) p¼ 0.013)
were independently associated with death.ath (event).
PRS 4 PRS 5 Overall
(n¼ 13) (n¼ 3) (n¼ 174)
2) 3.92 (0.601) 3.59 (0.959) 3.95 (0.549)
, 4.77] 4.10 [2.80, 4.90] 3.08 [3.00, 4.70] 4.00 [2.00, 5.50]
) 5.15 (7.13) 23.9 (26.9) 3.63 (4.88)
3, 14.6] 3.02 [1.50, 28.5] 13.8 [3.52, 54.5] 2.60 [0.553, 54.5]
) 14600 (17800) 5370 (5450) 1450 (6150)
8110] 5590 [39.8, 50000] 5140 [28.0, 10900] 39.5 [0.600, 50000]
) 8.78 (4.83) 37.7 (45.5) 6.56 (7.25)




Regression on the Prognostic Index (PRS) in the external validation cohort.
Slope SE p
Preoperative Risk Score 0.001 0.0007 0.076
Model misspecification/fit in the derivation and external validation cohort.
Derivation cohort n¼ 269a HR Coefficient SE 95% CI p
Serum albumin 0.76 0.279 0.150 0.55e0.99 0.047
NLR 1.05 0.050 0.018 1.02e1.09 0.009
LogN CA 19e9 1.33 0.281 0.041 1.22e1.45 <0.001
Tumr size (per cm) 1.12 0.112 0.026 1.06e1.18 <0.001
Validation cohort n¼355 HR Coefficient SE 95% CI p
Serum albumin 0.7003 0.35623 0.14900 0.523e0.9378 0.0168
NLR 1.0418 0.04099 0.01610 1.009e1.0753 0.0109
LogN CA 19e9 1.1584 0.14700 0.03440 1.083e1.2391 <0.0001
Tumr size (per cm) 0.0133 0.01324 0.00929 0.995e1.0319 0.1542
Likelihood ratio test¼ 32.69 on 4 df, p¼0.000001
Measures of discrimination (Harrel's c-index).
Harrell's c-index 95% CI
Preoperative Risk Score 0.6142853 0.5558e0.6723
Calibration function (Hosmer-Lemeshow goodness of fit test).
Observation Events (death) Expected p
n 355 174 173.9 0.175
NLR¼ Neutrophil to lymphocyte ration, SE¼Strandard Error, HR¼Hazare Ratio, CI¼ confidence interval, PRS¼Preoperative Risk Score, df¼ degrees of freedom.
a Data copied from the original publication [14].
Fig. 2. Receiver Operator Characteristics (ROC) curve for PRS and mortality. The Har-
rell's c-index, corresponding to the area under the ROC (AuROC) was 0.61 95%
CI(0.56e0.67).
R. Brustia et al. / European Journal of Surgical Oncology 46 (2020) 560e571568Model improvement
Within the previous analysis, the presence of steatosis was
independently associated with death. Given the increasing diffu-
sion of the assessment of steatosis on radiological preoperative
imaging (MRI or CT), we included this predictor parameter within a
new PRS to test its performance compared to the PRS alone.
Considering steatosis as binary (Y/N), the new PRS þ Steatosis is
calculated asfollows ¼ [9 þ (2.79  albumin) þ (0.50  NLR) þ (2.81  natural
logarithm CA 19-9) þ (1.12  tumor size) þ (0.53  steatosis)]. No
difference was observed between the auROC for PRS and
PRS þ Steatosis, displayed in Fig. 4: 0.614 (95%CI:0.53e0.67) vs
0.606 (95%CI:0.55e0.67) respectively, p¼ 0.66.
Given theunderrepresentationof the PRS class-risk4 (n¼ 22) and
5 (n¼ 5), with significant overlap in Kaplan-Meier strata, wemerged
these two groups in a single one PRS >30 (n¼ 27). The Kaplan-Meier
survival estimation with 4 class-risk is displayed in Fig. 5.
Discussion
ICC is a rare disease, and wewere challenged to organize a large
international cohort for external validation of a preoperative risk
score (PRS) of survival after LS for ICC, proposed by Sasaki et al. [14].
The PRS was originally obtained after random splitting a data frame
of 538 patients in a training and a validation cohort: besides a good
discrimination, the calibration of the original PRS was fair [14]. One
of the reasons explaining such results may be found in the absence
of a preemptive sample size calculation [18,19].
Our study allowed the external validation of the PRS and its
ability to class five risk groups of patients, based on a pre-operative
assessment of the disease. According to our analysis, this score
seems useful in clinical practice, and may help to decide in the
future whose patients could be considered or not for upfront sur-
gery. To be clear, we don't feel that clinicians (surgeons or oncol-
ogists) will refuse to offer a minor hepatic resection
(segmentectomy or left lateral section) even for high-risk class IV-V
patients: the debate is more likely to be on complex liver surgery
(major right or left hepatectomy, with or without associated biliary
or vascular procedures), or in case of repeated hepatectomy. The
PRS is intended to be a decision aid during multi-disciplinary team
meetings.
The methodological strength of our study relies in the fact that
the external validation was based on a larger independent cohort
(n¼ 355) than the derivation one (n¼ 269), and did not include any
Fig. 3. Kaplan-Meier survival estimation for the different PRS classes: PRS 0e9 (PRS_score¼ 1), PRS 10e19 (PRS_score¼ 2), PRS 20e29 (PRS_score¼ 3), PRS 30e39 (PRS_score¼ 4),
PRS 40 (PRS_score¼ 5).
Fig. 4. Receiver Operator Characteristics (ROC) curve comparing the PRS and the
improved version of PRS integrating steatosis (PRS þ Steatosis). No difference was
observed between the area under the ROC (AuROC) for PRS and PRS þ Steatosis: 0.614
(95%CI:0.53e0.67) vs 0.606 (95%CI:0.55e0.67) respectively, p ¼ 0.66.
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dictive performance of a published prediction model on a separate
dataset), we followed the methodology from Royston et al. [13] and
the reporting recommendations of the TRIPOD statement [15].
Taken altogether, these points reinforce the quality and usefulness
of the score validation process. The slope of the PI, Harrell's c-index
and the five separate strata in the KaplaneMeier curves suggested
poor but acceptable discrimination: this can be expected in such in
validation studies realized on large, multicenter international
retrospective cohorts, because of the different case-mix.
Although five classes of risk were defined, only three of them
(PRS class 1e3) appear clearly separated (in both derivation and
validation dataset), and potentially useful in clinical practice. In
particular, the observed survival rates at one year for PRS classes
1e3 were of 95.5%, 85.7% and 83.5%, while in PRS classes 4e5 were
74.8% and 66.7%, respectively. This discrimination is stable over the
time: at 3 years, with 72.4%, 55.0% and 42.5% for PRS classes 1e3
against 20.4% and 0% for PRS classes 4e5, respectively, and at five
years, with 55.3%, 42.1% and 26.4% for PRS classes 1e3 against 20.4%
and 0% for PRS classes 4e5, respectively. Given the underrepre-
sentation and strata overlap of the two latter classes, we merged
them together (Fig. 5): a reduced model with 4 classes may prob-
ably be more useful than the original one.
When considering the four prognostic variables included in the
PRS score, half of them (CA 19-9 and tumor size) are directly related
to the tumoral features, while the two others (albumin, NLR) are
dependent from the patient condition or to the underlying liver
disease. Indeed, 20% of the included patients had a significant liver
Fig. 5. Kaplan-Meier survival estimation after merging the strata of the previous class 4 and 5 in a single one (Class 4, PRS>30): PRS 0e9 (PRS_score¼ 1), PRS 10e19 (PRS_score¼ 2),
PRS 20e29 (PRS_score¼ 3), PRS> 30 (PRS_score¼ 4).
R. Brustia et al. / European Journal of Surgical Oncology 46 (2020) 560e571570fibrosis (F I-III) or cirrhosis (F IV). These latter values in particular
can fluctuate according the patient's general condition, and are
probably less relevant than those - more objective - related to the
tumoral features. In future studies, it could be interesting to focus
on the dynamic evolution of the PRS score: at the time of the
diagnosis, and after the introduction of a neo-adjuvant treatment
and/or a prehabilitation program. Similar to a “test of time”, if there
is a change of PRS class after such treatment, it would possible to
consider a more aggressive treatment for this category of patients.
When focusing on preoperative variables, univariate and
multivariate Cox analyses showed significant correlation with sur-
vival for NLR and CA 19-9 in this validation cohort. In contrast with
the original derivation cohort [14] and to previously published
studies, tumor size [20] and albumine [21] were not significantly
associatedwith survival. The lack of statistical significance for these
two predictors may be due to the different historical period
(1990e2015 derivation cohort, versus 2001e2018 validation
cohort) and case-mix: even in the absence of statistical analyses, a
simple comparison reveals how patients in the validation cohort
were older, had lower CA 19-9 level and higher rate of T stage II-IV,
R1 resection and poor histological differentiation as compared to
the derivation cohort. These differences represent classical limita-
tions and biases of any retrospective multicenter cohort study
realized over a long time-period.
Anyhow, the observation of very similar c-indexes in the original
(0.69, 95%CI:0.65e0.74) and external cohort (0.61, 95%
CI:0.56e0.67) despite the different characteristics of both cohorts,
allows to speculate the reproducibility e and therefore the use-
fulness e of such a PRS.
Last, there are still two potential ways to improve the perfor-
mance of the PRS. We tried to integrate steatosis into the score
(PRS þ Steatosis, Fig. 4), but the results were not different from the
PRS alone. Recently Lunsford et al. [22] showed some promisingresults of liver transplantation after neo-adjuvant treatment for
advanced ICC, and this is probably the room for improvement of the
PRS. However neo-adjuvant regiment was administered only in
some 6% of our patient's cohort, with heterogeneity in molecule,
cycles and duration: results of prospective trials are urgently
needed, to include or not neo-adj treatment in the PRS. Another
way to test the usefulness of the PRS e as it is e might be its dy-
namic evolution after a neo-adjuvant treatment: a patient jumping
from a mid-class risk to a low-class risk after neo-adjuvant treat-
ment could be considered as a good prognostic sign, authorizing
some heavier treatments or surgical resection.
To resume, the PRS model has acceptable performance, is
generalizable among different ICC populations and moreover it is
easy-to-use through any digital spreadsheet. As a perspective, PRS
paves the way to a tailored strategy, avoiding upfront surgery for
class 4e5 patients and proposing aggressive surgery for class 1
patients. Further studies are needed to ascertain if class 2e3 pa-
tients may benefit of an induction treatment, including preopera-
tive neoadjuvant chemotherapy, to seek for an improvement of the
parameters before any potential surgery.Declaration of competing interest
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